A Study to Assess the Efficacy and Safety of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Progressive Pulmonary Fibrosis (PPF)
← catalyst calendarNCT07805785 · readout in 1,456 d
Sponsored by Insmed Incorporated (industry) · INSM — their whole pipeline →.
Phase
Phase 3
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
800estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-09-04
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-12-01 | estimated | When the study began enrolling |
| Primary completion | 2030-08-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-08-31 | estimated | The whole study's end, after follow-up |
| First posted | 2026-09-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-09-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Progressive Pulmonary Fibrosis
- Interstitial Lung Disease
Interventions
- Drug: Treprostinil Palmitil Inhalation Powder — also filed as INS1009
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFChange From Baseline in Absolute Forced Vital Capacity (FVC) at Week 52
measured Baseline, Week 52
Related
INSM · their whole pipeline · Who in Congress owns INSM? · Executive-branch trades in INSM
INSM's other studiesmost recently updated first
- A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH) Phase 3 · Recruiting
- An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH) Phase 2/3 · Active, not recruiting
- Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) Phase 3 · Recruiting
- A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of INS1033 in Healthy Participants Phase 1 · Not yet recruiting
- An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) Phase 3 · Recruiting
Permalink · INSM's whole pipeline · Catalyst calendar · Every registered study · What changed